Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Tonix Pharmaceuticals (Nasdaq: TNXP) announced approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective at market open on March 3, 2026, under the existing ticker TNXP.

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) announced approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective at market open on March 3, 2026, under the existing ticker TNXP.

The company says the uplisting reflects compliance with higher financial and governance standards and may enhance visibility, liquidity and institutional access. Tonix is a commercial-stage biotech with recently approved TONMYA™ for fibromyalgia and marketed acute migraine products, plus multiple investigational CNS and immunology programs.

Positive

• Uplisting to Nasdaq Global Select Market effective March 3, 2026
• TONMYA approved as first new fibromyalgia treatment in over 15 years
• Company is commercial-stage with marketed migraine products

Negative

• Pipeline candidates remain investigational; efficacy and safety not established

Argus Mar 3 session

-0.29% close to close Open Argus

Details

News Market Reaction – TNXP

On Mar 3, the day this news came out, TNXP closed 0.29% below the previous close.

Data tracked by StockTitan Argus for the Mar 3 session.

Key Figures

Nasdaq Global Select start: March 3, 2026 TONMYA dose: 2.8 mg Fibromyalgia innovation gap: more than 15 years +2 more

Nasdaq Global Select start

March 3, 2026

Date trading expected to commence on Nasdaq Global Select Market

TONMYA dose

2.8 mg

Cyclobenzaprine HCl sublingual tablet strength for fibromyalgia

Fibromyalgia innovation gap

more than 15 years

Time since last new fibromyalgia treatment before TONMYA

TONMYA trials phase

Phase 2

Ongoing trials in major depressive disorder and acute stress disorder

TNX-2900 stage

Phase 2 ready

Development stage for Prader-Willi syndrome program

Historical Context

5 past events · Latest: Feb 25

5 events

1. Feb 25

   Investor conferences

   24h Move

   +3.9%

   Management participation at two March 2026 investor conferences.

2. Jan 30

   Clinical data update

   24h Move

   -5.4%

   Positive Phase 3 RESILIENT data presentation for TONMYA in fibromyalgia.

3. Jan 06

   Investor conferences

   24h Move

   +0.9%

   CEO presentations and meetings at two January 2026 investor conferences.

4. Dec 29

   Equity offering

   24h Move

   +0.1%

   $20.0 million registered direct offering to fund commercialization and pipeline.

5. Dec 29

   Pipeline update

   24h Move

   +0.1%

   Program updates for TNX-4800 Lyme disease prophylaxis candidate.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq global select market, nasdaq capital market, fibromyalgia, central nervous system (cns), +4 more

8 terms

nasdaq global select market financial

"transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

nasdaq capital market financial

"transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

fibromyalgia medical

"the first new treatment for fibromyalgia in more than 15 years"

Fibromyalgia is a long-term condition that causes widespread body pain, extreme tiredness, and problems with sleep, memory and mood; people often feel unusually sensitive to normal touch or pressure, and symptoms can fluctuate from day to day. It matters to investors because it affects workforce productivity, healthcare spending, and demand for treatments—so advances in diagnostics, drugs, or care delivery can change market size and company prospects, much like a fuel problem that reduces a car’s performance and reliability.

central nervous system (cns) medical

"focused on central nervous system (CNS) and immunology treatments"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

monoclonal antibody medical

"including monoclonal antibody TNX-4800 for Lyme disease prophylaxis"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

cd40 ligand inhibitor medical

"TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection"

A CD40 ligand inhibitor is a drug that blocks the CD40 ligand, a protein used by immune cells to send activation and inflammatory signals; think of it as turning down an alarm bell that rallies the immune system. Investors care because these drugs aim to treat autoimmune diseases, transplant rejection or inflammatory conditions, so their clinical trial results, safety profile and regulatory approval prospects directly affect a company’s future revenue potential and development risk.

phase 2 clinical trials medical

"maximizing the science behind TONMYA in Phase 2 clinical trials"

Phase 2 clinical trials are mid-stage tests of a new treatment in a larger group of patients to assess whether it works and to further evaluate safety and dosing. Think of it like a more serious test drive after basic checks: success suggests the treatment has real potential and justifies larger, more expensive late-stage trials, which can increase a drug developer’s value to investors, while failure often leads to sharp declines in outlook.

prader-willi syndrome medical

"TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market is expected to commence at the open of market on March 3, 2026, under the Company’s existing ticker symbol “TNXP.”

The uplisting to the Nasdaq Global Select Market reflects the Company’s compliance with the Nasdaq Global Select Market’s higher financial and corporate governance standards. The transition to this higher tier of the Nasdaq market may enhance the Company’s visibility among institutional investors, improve liquidity and broaden market recognition.

“Uplisting to the Nasdaq Global Select Market is an important milestone for Tonix,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We look forward to leveraging this enhanced platform to drive growth and create value for our shareholders. We're grateful for the support that has brought us here and excited about what's ahead.”

The Nasdaq Global Select Market is the highest of the three Nasdaq market tiers and is designed for companies that meet higher financial, liquidity and corporate governance requirements than those of the Nasdaq Capital Market and the Nasdaq Global Market. The Company believes that trading on this tier will further enhance its reputation with customers, partners and investors. Companies at this level may experience increased trading volumes and greater access to institutional investors. Meeting the Global Select Market’s higher financial and corporate governance standards may also signal to the market that a company has achieved financial and operational growth.

Tonix Pharmaceuticals Holding Corp.*
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals 
investor.relations@tonixpharma.com 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
brian.korb@astrpartners.com 

Media Contacts
Ray Jordan 
Putnam Insights 
ray@putnaminsights.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the March 3, 2026 uplisting to Nasdaq Global Select mean for TNXP shareholders?

The uplisting means TNXP will trade on a higher Nasdaq tier starting March 3, 2026. According to the company, the move reflects compliance with stronger financial and governance standards and may increase visibility and institutional investor interest.

When will Tonix (TNXP) begin trading on the Nasdaq Global Select Market?

TNXP is expected to begin trading on the Nasdaq Global Select Market at market open on March 3, 2026. According to the company, the ticker symbol will remain TNXP and trading starts under the existing symbol.

Why did Tonix (TNXP) transfer its listing to the Nasdaq Global Select Market?

Tonix says the transfer reflects compliance with higher financial and corporate governance standards required on the Global Select tier. According to the company, the change may enhance market recognition and access to institutional investors.

How might TNXP's uplisting affect liquidity and institutional interest in the stock?

The uplisting may improve liquidity and institutional access by listing on a higher-tier market. According to the company, Global Select status can increase trading volumes and broaden recognition among institutional investors.

What is the significance of TONMYA approval mentioned in the March 3, 2026 announcement for TNXP?

TONMYA is highlighted as the company's recently approved flagship medicine for fibromyalgia. According to the company, TONMYA is the first new fibromyalgia treatment in over 15 years and supports their commercial-stage profile.

What clinical and pipeline programs does Tonix (TNXP) list in the announcement?

Tonix lists CNS and immunology programs including Phase 2-ready TNX-2900 and monoclonal TNX-4800 and TNX-1500. According to the company, these candidates are investigational and have not established efficacy or safety.